Drug intelligence / Profile preview

EG-501

Development stage: Phase 2
Lead developer: Shenzhen Eglin Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

EG-501 is an oral, low-affinity NMDA receptor antagonist developed by Evergreen Therapeutics for the treatment of cognitive impairment in patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Developed using AI technology, the drug aims to address the "brain fog" and cognitive dysfunction associated with lupus, which currently has no FDA-approved therapies. In clinical studies, EG-501 has shown significant improvement in RBANS total scores compared to placebo, demonstrating efficacy in restoring cognitive function. It targets the NMDA receptor, with specific insights gained into the role of the GRIN2A subunit in neurological and immunological diseases.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)GRIN2A (NMDA receptor subunit 2A)

Beyond the preview

Go deeper on EG-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG-501.

Explore the full profile